Chinese Medicine Treat for Hypertensive Renal Injury

• Status: Not yet recruiting
• Trial end date: 2021-12-30
• Target enrollment: 0
• Participant gender: All

Summary

This study evaluates whether the traditional chinese medicine (Qianyangyuyin formula) could prevent and treat early renal injury in patients with hypertension and microalbuminuria (defined as a urinary albumin to creatinine ratio between 30 and 300 mg/g) based on standard antihypertensive treatment.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Jiangsu Province Hospital of Traditional Chinese Medicine
• Collaborators: Ministry of Science and Technology of the People´s Republic of China; The affiliated hospital of Liaoning University of Traditional Chinese Medicine; The First Affiliated Hospital of Henan University of Traditional Chinese Medicine
• Treatments: Losartan

Criteria

Inclusion Criteria:

• Subject has primary hypertension(grades 2-3)

• Subject has microalbuminuria [defined as a urinary albumin/creatinine ratio (UACR) between 30 and 300mg/g, and a eGFR at least 60ml/(min∙1.73m2)]

• Subject has ascendant hyperactivity of liver Yang or Yin deficiency in TCM syndrome

• Subject voluntarily participates in the trial and signs informed consent

Exclusion Criteria:

• Subject has secondary hypertension

• Subject with pregnancy or lactating

• Subject has serious life-threatening diseases, such as acute myocardial infarction, stroke, heart failure (NYHA IV), and malignant arrhythmia

• Subject's liver function (AST or ALT) is 2 times greater than normal value

• Subject has history of mental illness

• Subject currently participates in other drug clinical trials